Study Evaluating PRA-027 Multiple Ascending Doses In Cycling And Postmenopausal Women

Summary

This is the first multiple-dose study in humans with PRA-027. This study will provide an assessment of the safety, tolerability, pharmacokinetics (how the drug is absorbed, metabolized and excreted by the body) and pharmacodynamics (a measure of whether the drug is active in the body) of PRA-027 after administration of 28 days of oral doses in women of childbearing potential (cycling) or postmenopausal women.

Timeline

Start

2007-11

Primary completion

2008-12

Completion

2008-12

Drugs

Indications